August 15, 2023 7:41am
Sentiment across the globe was downbeat after disappointing data out of China and a surprise rate cut from the country’s central bank
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Pre-open Indications: 1 Negative, 1 Positive and 1 Sell into Strength
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Never leave an investor uninformed!
Never leave an investor uninformed!
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday
Dow futures are DOWN -0.61% or (-214 point), S&P futures are DOWN -0.57% or (-25 points) and NASDAQ futures are DOWN -0.53% or (-80 points) early in the pre-open – so far
U.S. stock futures fell Tuesday,
European markets were lower Tuesday as investors weigh data from the U.K.,
Asia Pacific markets mixed as Japan GDP beats expectation; China July data disappoints.
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Last night, indexes rose after being up and down yet, closing positive as the Dow closed UP +26.23 or +0.07%, the S&P closed UP +25.67 or +0.58% while the Nasdaq closed UP +143.48 points (+1.05%)
Economic Data Docket: Economists expect report on monthly retail sales to show growth accelerated to 0.4% in July from 0.2% in June.
Monday’s (8/14) RegMed Investors’ (RMi) closing bell: “another week’s beginning of share pricing sector losers … https://www.regmedinvestors.com/articles/13077
Ebb and flow:
Q3: August – 2 positive and 8 negative closes
· July - 1 holiday, 12 positive and 8 negative close
Q2/23 -
· June -1 Holiday, 8 negative and 11 positive closes
· May – 10 negative and 12 positive closes
· April ended - 1 holiday, 8 positive close and 11 negative closes
Q1/23 –-
· March – ended with 10 positive and 13 negative closes
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Sell into Strength:
Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Blueprint Medicine (BLMC) closed up +$1.88 with a positive m+$0.74 or +1.44% aftermarket indication.
Positive Indication:
Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Ionis Pharmaceuticals (IONS) closed down-$0.34 with a positive +$0.37 or +0.93% pre-open indication.
Negative Indication:
Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Vericel (VCEL) closed up +$0.46 with a negative -$0.64 or -1.99% aftermarket indication
The BOTTOM LINE:
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all, as I try to keep it simple and short!
It “ain’t” been a good August for the cell and gene therapy sector as it suffers 2 positive and 8 negative closes so far.
There's ALSO nothing wrong with standing pat in the short run, holding on to sizable existing exposure.
I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
